北京时间7月29日,贝达药业战略合作伙伴EyePoint Pharmaceuticals, Inc.(纳斯达克股票代码:EYPT,以下简称“EyePoint”)宣布,其评估DURAVYU™治疗湿性年龄相关性黄斑变性(湿性AMD)效果的关键性III期临床试验LUCIA已全部完成患者入组。继首项关键性临床试验LUGANO于2025年5月完成入组后,第二项关键性临床试验LUCIA也已顺利完成入组,在短短...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.